Summer 2021 (Volume 31, Number 2)
Update on CRA Initiatives
The Canadian Rheumatology Association (CRA) is
pleased to provide the following updates:
Pediatric Choosing Wisely Recommendations
Over the last several months, the CRA Choosing Wisely
Pediatric subcommittee has developed a list of seven
recommendations that clinicians and patients should
consider regarding resource stewardship. This list will
be published on the Choosing Wisely Canada website:
choosingwiselycanada.org/. The development of this list was a
collaborative endeavour, involving not only CRA members
but an Advanced Clinical Practitioner in Arthritis Care
(ACPAC), parent and patient representative as well.
Position Statement on Virtual Care
The CRA has published a position statement on virtual care.
The purpose of the position statement is to support responsible,
appropriate virtual health usage by Canadian rheumatologists.
The position statement recognizes that rheumatologists
will and should continue to use virtual health
post-pandemic; identifies the benefits of virtual health and
the need for ongoing support; and recognizes the importance
of establishing virtual health practice standards. Visit
the following link for more information: rheum.ca/wp-content/uploads/2021/04/EN-CRA-Position-Statement-on-Virtual-Care_April-29_2021.pdf. Best practice statements for virtual care
in rheumatology are currently being finalized and will be
another valuable resource for CRA members coming soon!
Call for 2022 ASM Workshop Proposals
Members of the CRA and Arthritis Health Professions
Association (AHPA) are invited to share their knowledge
and experience by submitting a workshop proposal for the
upcoming 2022 Annual Scientific Meeting. ASM interactive
workshops are intended to bring the rheumatology
community together to discuss topics and issues that optimize
patient care. For more information and to submit a
proposal, please visit rheum.ca. The deadline to submit is
July 30, 2021.
Updated CRA Recommendation on COVID-19
Vaccination in Persons with Autoimmune
The CRA GRADE recommendation, originally published
on February 13, 2021, has now been updated to include
the AstraZeneca and Johnson & Johnson vaccines and can
be found on the CRA website at rheum.ca/resources/publications/.
Additionally, the manuscript has been published
in the Journal of Rheumatology and is available to read here:
CRA Decision Aid for the COVID-19 Vaccine that accompanies
this guidance is being updated and expanded to
include considerations for pediatric patients. This tool is
currently under development but may in fact be published by the time of this publication. Please check the CRA website
Updated CRA Position Statement on COVID-19
In addition to the CRA GRADE recommendation on COVID-19 Vaccination, CRA has also published an update
to the Position Statement on COVID-19 Vaccination to
include the expanded use of the Pfizer-BioNTech vaccine
in children between the ages of 12-15 years. The Position
Statement is a document intended not only for clinicians,
but for the public and decision-makers as well and is often
used as an advocacy tool. The Position Statement has
been updated several times since its first publication on
December 31, 2020, to reflect changing recommendations
and to advocate for the prioritization of vaccination and
early second doses for immunocompromised individuals.
Visit rheum.ca/resources/publications/ to read the updated
CRA Position Statement.